1
|
Rha AK, Kan SH, Andrade-Heckman P, Christensen CL, Harb JF, Wang RY. Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells. Mol Genet Metab 2024; 143:108568. [PMID: 39303319 DOI: 10.1016/j.ymgme.2024.108568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 07/19/2024] [Accepted: 08/20/2024] [Indexed: 09/22/2024]
Abstract
GM1 gangliosidosis is an autosomal recessive neurodegenerative lysosomal storage disease caused by pathogenic variants in the GLB1 gene, limiting the production of active lysosomal β-galactosidase. Phenotypic heterogeneity is due in part to variant type, location within GLB1, and the amount of residual enzyme activity; in the most severe form, death occurs in infancy. With no FDA approved therapeutics, development of efficacious strategies for the disease is pivotal. CRISPR/Cas based approaches have revolutionized precision medicine and have been indispensable to the development of treatments for several monogenic disorders with bespoke strategies central to current research pipelines. We used CRISPR/Cas-adenine base editing to correct the GLB1 c.380G>A (p.Cys127Tyr) variant in patient-derived dermal fibroblasts compound heterozygous with the GLB1 c.481T>G (p.Trp161Gly) pathogenic variant. Nucleofection of plasmids encoding the target sgRNA and ABEmax restored the canonical guanine (32.2 ± 2.2 % of the target allele) and synthesis of active β-galactosidase. Analysis of cellular markers of pathology revealed normalization of both primary glycoconjugate storage and lysosomal pathology. Furthermore, analysis of off-target sites nominated by the in silico tools Cas-OFFinder and/or CRISTA revealed no significant editing or indels. This study supports the use of CRISPR/Cas-based approaches for the treatment of GM1 gangliosidosis, and provides foundational data for future translational studies.
Collapse
Affiliation(s)
- Allisandra K Rha
- Research Institute, Children's Hospital of Orange County, Orange, CA 92868, United States
| | - Shih-Hsin Kan
- Research Institute, Children's Hospital of Orange County, Orange, CA 92868, United States
| | - Perla Andrade-Heckman
- Research Institute, Children's Hospital of Orange County, Orange, CA 92868, United States
| | - Chloe L Christensen
- Research Institute, Children's Hospital of Orange County, Orange, CA 92868, United States
| | - Jerry F Harb
- Research Institute, Children's Hospital of Orange County, Orange, CA 92868, United States
| | - Raymond Y Wang
- Division of Metabolic Disorders, Children's Hospital of Orange County Specialists, Orange, CA 92868, United States; Department of Pediatrics, University of California-Irvine School of Medicine, Irvine, CA 92697, United States.
| |
Collapse
|
2
|
Carrier Rate and Mutant Allele Frequency of GM1 Gangliosidosis in Miniature Shiba Inus (Mame Shiba): Population Screening of Breeding Dogs in Japan. Animals (Basel) 2022; 12:ani12101242. [PMID: 35625088 PMCID: PMC9137666 DOI: 10.3390/ani12101242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 05/06/2022] [Accepted: 05/10/2022] [Indexed: 02/05/2023] Open
Abstract
GM1 gangliosidosis is a progressive, recessive, autosomal, neurodegenerative, lysosomal storage disorder that affects the brain and multiple systemic organs due to an acid β-galactosidase deficiency encoded by the GLB1 gene. This disease occurs in the Shiba Inu breed, which is one of the most popular traditional breeds in Japan, due to the GLB1:c.1649delC (p.P550Rfs*50) mutation. Previous surveys performed of the Shiba Inu population in Japan found a carrier rate of 1.02–2.94%. Currently, a miniature type of the Shiba Inu called “Mame Shiba”, bred via artificial selection to yield smaller individuals, is becoming more popular than the standard Shiba Inu and it is now one of the most popular breeds in Japan and China. The GM1 gangliosidosis mutation has yet to be surveyed in the Mame Shiba population. This study aimed to determine the frequency of the mutant allele and carrier rate of GM1 gangliosidosis in the Mame Shiba breed. Blood samples were collected from 1832 clinically healthy adult Mame Shiba Inus used for breeding across 143 Japanese kennels. The genotyping was performed using a real-time PCR assay. The survey found nine carriers among the Mame Shibas, indicating that the carrier rate and mutant allele frequency were 0.49% and 0.00246, respectively. This study demonstrated that the mutant allele has already been inherited by the Mame Shiba population. There is a risk of GM1 gangliosidosis occurrence in the Mame Shiba breed if breeders use carriers for mating. Further genotyping surveys are necessary for breeding Mame Shibas to prevent the inheritance of this disease.
Collapse
|
3
|
Tamura S, Tamura Y, Nakamoto Y, Hasegawa D, Tsuboi M, Uchida K, Yabuki A, Yamato O. Positioning Head Tilt in Canine Lysosomal Storage Disease: A Retrospective Observational Descriptive Study. Front Vet Sci 2022; 8:802668. [PMID: 34970622 PMCID: PMC8712568 DOI: 10.3389/fvets.2021.802668] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 11/25/2021] [Indexed: 11/13/2022] Open
Abstract
Positioning head tilt is a neurological sign that has recently been described in dogs with congenital cerebellar malformations. This head tilt is triggered in response to head movement and is believed to be caused by a lack of inhibition of the vestibular nuclei by the cerebellar nodulus and ventral uvula (NU), as originally reported cases were dogs with NU hypoplasia. We hypothesized that other diseases, such as lysosomal storage diseases that cause degeneration in the whole brain, including NU, may cause NU dysfunction and positioning head tilt. Videos of the clinical signs of canine lysosomal storage disease were retrospectively evaluated. In addition, post-mortem NU specimens from each dog were histopathologically evaluated. Nine dogs were included, five with lysosomal storage disease, two Chihuahuas with neuronal ceroid lipofuscinosis (NCL), two Border Collies with NCL, one Shikoku Inu with NCL, two Toy Poodles with GM2 gangliosidosis, and two Shiba Inus with GM1 gangliosidosis. Twenty-eight videos recorded the clinical signs of the dogs. In these videos, positioning head tilt was observed in seven of nine dogs, two Chihuahuas with NCL, one Border Collie with NCL, one Shikoku Inu with NCL, one Toy Poodle with GM2 gangliosidosis, and two Shiba Inus with GM1 gangliosidosis. Neuronal degeneration and loss of NU were histopathologically confirmed in all diseases. As positioning head tilt had not been described until 2016, it may have been overlooked and may be a common clinical sign and pathophysiology in dogs with NU dysfunction.
Collapse
Affiliation(s)
| | | | - Yuya Nakamoto
- Neuro Vets Animal Neurology Clinic, Kyoto, Japan.,Veterinary Surgery, Graduate School of Life and Environmental Science, Osaka Prefecture University, Sakai, Japan
| | - Daisuke Hasegawa
- Laboratory of Veterinary Radiology, Nippon Veterinary and Life Science University, Tokyo, Japan
| | - Masaya Tsuboi
- Laboratory of Veterinary Pathology, Graduate School of Agriculture and Life Science, University of Tokyo, Tokyo, Japan
| | - Kazuyuki Uchida
- Laboratory of Veterinary Pathology, Graduate School of Agriculture and Life Science, University of Tokyo, Tokyo, Japan
| | - Akira Yabuki
- Laboratory of Clinical Pathology, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan
| | - Osamu Yamato
- Laboratory of Clinical Pathology, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
4
|
Rha AK, Maguire AS, Martin DR. GM1 Gangliosidosis: Mechanisms and Management. Appl Clin Genet 2021; 14:209-233. [PMID: 33859490 PMCID: PMC8044076 DOI: 10.2147/tacg.s206076] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 01/15/2021] [Indexed: 01/10/2023] Open
Abstract
The lysosomal storage disorder, GM1 gangliosidosis (GM1), is a neurodegenerative condition resulting from deficiency of the enzyme β-galactosidase (β-gal). Mutation of the GLB1 gene, which codes for β-gal, prevents cleavage of the terminal β-1,4-linked galactose residue from GM1 ganglioside. Subsequent accumulation of GM1 ganglioside and other substrates in the lysosome impairs cell physiology and precipitates dysfunction of the nervous system. Beyond palliative and supportive care, no FDA-approved treatments exist for GM1 patients. Researchers are critically evaluating the efficacy of substrate reduction therapy, pharmacological chaperones, enzyme replacement therapy, stem cell transplantation, and gene therapy for GM1. A Phase I/II clinical trial for GM1 children is ongoing to evaluate the safety and efficacy of adeno-associated virus-mediated GLB1 delivery by intravenous injection, providing patients and families with hope for the future.
Collapse
Affiliation(s)
- Allisandra K Rha
- Scott-Ritchey Research Center, Auburn University, Auburn, AL, 36849, USA
| | - Anne S Maguire
- Scott-Ritchey Research Center, Auburn University, Auburn, AL, 36849, USA
- Department of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, AL, 36849, USA
| | - Douglas R Martin
- Scott-Ritchey Research Center, Auburn University, Auburn, AL, 36849, USA
- Department of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, AL, 36849, USA
| |
Collapse
|
5
|
Wang P, Henthorn PS, Galban E, Lin G, Takedai T, Casal M. Canine GM2-Gangliosidosis Sandhoff Disease Associated with a 3-Base Pair Deletion in the HEXB Gene. J Vet Intern Med 2017; 32:340-347. [PMID: 29106755 PMCID: PMC5787214 DOI: 10.1111/jvim.14862] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Revised: 09/02/2017] [Accepted: 09/21/2017] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND GM2-gangliosidosis is a fatal neurodegenerative lysosomal storage disease (LSD) caused by deficiency of either β-hexosaminidase A (Hex-A) and β-hexosaminidase B (Hex-B) together, or the GM2 activator protein. Clinical signs can be variable and are not pathognomonic for the specific, causal deficiency. OBJECTIVES To characterize the phenotype and genotype of GM2-gangliosidosis disease in an affected dog. ANIMALS One affected Shiba Inu and a clinically healthy dog. METHODS Clinical and neurologic evaluation, brain magnetic resonance imaging (MRI), assays of lysosomal enzyme activities, and sequencing of all coding regions of HEXA, HEXB, and GM2A genes. RESULTS A 14-month-old, female Shiba Inu presented with clinical signs resembling GM2-gangliosidosis in humans and GM1-gangliosidosis in the Shiba Inu. Magnetic resonance imaging (MRI) of the dog's brain indicated neurodegenerative disease, and evaluation of cerebrospinal fluid (CSF) identified storage granules in leukocytes. Lysosomal enzyme assays of plasma and leukocytes showed deficiencies of Hex-A and Hex-B activities in both tissues. Genetic analysis identified a homozygous, 3-base pair deletion in the HEXB gene (c.618-620delCCT). CONCLUSIONS AND CLINICAL IMPORTANCE Clinical, biochemical, and molecular features are characterized in a Shiba Inu with GM2-gangliosidosis. The deletion of 3 adjacent base pairs in HEXB predicts the loss of a leucine residue at amino acid position 207 (p.Leu207del) supporting the hypothesis that GM2-gangliosidosis seen in this dog is the Sandhoff type. Because GM1-gangliosidosis also exists in this breed with almost identical clinical signs, genetic testing for both GM1- and GM2-gangliosidosis should be considered to make a definitive diagnosis.
Collapse
Affiliation(s)
- P Wang
- Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - P S Henthorn
- Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - E Galban
- Section of Neurology & Neurosurgery, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - G Lin
- Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - T Takedai
- Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - M Casal
- Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
6
|
Kolicheski A, Johnson GS, Villani NA, O'Brien DP, Mhlanga-Mutangadura T, Wenger DA, Mikoloski K, Eagleson JS, Taylor JF, Schnabel RD, Katz ML. GM2 Gangliosidosis in Shiba Inu Dogs with an In-Frame Deletion in HEXB. J Vet Intern Med 2017; 31:1520-1526. [PMID: 28833537 PMCID: PMC5598891 DOI: 10.1111/jvim.14794] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Revised: 06/08/2017] [Accepted: 06/27/2017] [Indexed: 11/28/2022] Open
Abstract
Consistent with a tentative diagnosis of neuronal ceroid lipofuscinosis (NCL), autofluorescent cytoplasmic storage bodies were found in neurons from the brains of 2 related Shiba Inu dogs with a young‐adult onset, progressive neurodegenerative disease. Unexpectedly, no potentially causal NCL‐related variants were identified in a whole‐genome sequence generated with DNA from 1 of the affected dogs. Instead, the whole‐genome sequence contained a homozygous 3 base pair (bp) deletion in a coding region of HEXB. The other affected dog also was homozygous for this 3‐bp deletion. Mutations in the human HEXB ortholog cause Sandhoff disease, a type of GM2 gangliosidosis. Thin‐layer chromatography confirmed that GM2 ganglioside had accumulated in an affected Shiba Inu brain. Enzymatic analysis confirmed that the GM2 gangliosidosis resulted from a deficiency in the HEXB encoded protein and not from a deficiency in products from HEXA or GM2A, which are known alternative causes of GM2 gangliosidosis. We conclude that the homozygous 3‐bp deletion in HEXB is the likely cause of the Shiba Inu neurodegenerative disease and that whole‐genome sequencing can lead to the early identification of potentially disease‐causing DNA variants thereby refocusing subsequent diagnostic analyses toward confirming or refuting candidate variant causality.
Collapse
Affiliation(s)
- A Kolicheski
- Department of Veterinary Pathobiology, University of Missouri, Columbia, MO
| | - G S Johnson
- Department of Veterinary Pathobiology, University of Missouri, Columbia, MO
| | - N A Villani
- Department of Veterinary Pathobiology, University of Missouri, Columbia, MO
| | - D P O'Brien
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO
| | | | - D A Wenger
- Department of Neurology, Jefferson Medical College, Philadelphia, PA
| | - K Mikoloski
- Pittsburgh Veterinary Specialty and Emergency Center, Pittsburgh, PA
| | - J S Eagleson
- Veterinary Specialty and Emergency Center, Blue Pearl Veterinary Partners, Levittown, PA
| | - J F Taylor
- Division of Animal Sciences, University of Missouri, Columbia, MO
| | - R D Schnabel
- Division of Animal Sciences and Informatics Institute, University of Missouri, Columbia, MO
| | - M L Katz
- Mason Eye Institute, University of Missouri, Columbia, MO
| |
Collapse
|
7
|
Satoh H, Yamato O, Asano T, Yamasaki M, Maede Y. Increased Concentration of GM1-Ganglioside in Cerebrospinal Fluid in Dogs with GM1- and GM2-Gangliosidoses and its Clinical Application for Diagnosis. J Vet Diagn Invest 2016; 16:223-6. [PMID: 15152837 DOI: 10.1177/104063870401600308] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
GM1- and GM2-gangliosidoses are lethal lysosomal diseases that are caused by a defect of acid hydrolases, resulting in the intralysosomal accumulation of the specific physiological substrates, GM1- and GM2-gangliosides, respectively. In the present study a method for the diagnosis of canine GM1-gangliosidosis was established using canine cerebrospinal fluid (CSF). The concentration of GM1-ganglioside in CSF was determined by thin-layer chromatography–enzyme immunostaining using biotin-conjugated cholera toxin B, which specifically binds with GM1-ganglioside. The concentration of CSF GM1-ganglioside was increased in Shiba dogs with GM1-gangliosidosis, and the increased level was approximately proportional to the age of the dogs. The concentration was high in the affected dog even at 5 months of age, when Shiba dogs with GM1-gangliosidosis first manifest neurologic signs. In addition, the concentration of CSF GM1-ganglioside in a dog with the GM2-gangliosidosis 0 variant (Sandhoff disease) was also 7 times the normal level. From these results it was concluded that this laboratory technique enables a definitive and early diagnosis of canine GM1-gangliosidosis even if tissues and organs cannot be obtained. However, because GM1-ganglioside can also be elevated in cases of GM2-gangliosidosis, it is necessary to assay for specific enzyme deficiencies to definitively separate GM1- from GM2-gangliosidosis.
Collapse
Affiliation(s)
- Hiroyuki Satoh
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan
| | | | | | | | | |
Collapse
|
8
|
Yamato O, Jo EO, Shoda T, Yamasaki M, Maede Y. Rapid and Simple Mutation Screening of GM1 Gangliosidosis in Shiba Dogs by Direct Amplification of Deoxyribonucleic Acid from Various Forms of Canine Whole-Blood Specimens. J Vet Diagn Invest 2016; 16:469-72. [PMID: 15460336 DOI: 10.1177/104063870401600520] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This report describes a rapid and simple method for mutation screening of GM1 gangliosidosis in Shiba dogs by direct amplification of DNA from canine whole-blood specimens using a novel polymerase chain reaction (PCR) reagent cocktail, which can eliminate the DNA extraction process and amplify the genomic DNA directly from human or murine whole blood. The strategy of this mutation screening is based on the identification of a nucleotide deletion by restriction enzyme analysis, coupled with the direct PCR amplification. The target sequence of the canine β-galactosidase gene could be amplified directly from various forms of canine whole-blood specimens, including anticoagulated blood, blood stored frozen for 1 year, dried blood held in filter paper for 1 year at room temperature, and dry powder of blood stripped from Giemsa-stained blood films, which had been prepared 10 years earlier, resulting in the determination of genotypes in all the specimens. This method simplified the molecular diagnosis and carrier screening of GM1 gangliosidosis in Shiba dogs, making it simple to examine specimens from the large, widely distributed population of these dogs.
Collapse
Affiliation(s)
- Osamu Yamato
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan
| | | | | | | | | |
Collapse
|
9
|
Uddin MM, Arata S, Takeuchi Y, Chang HS, Mizukami K, Yabuki A, Rahman MM, Kohyama M, Hossain MA, Takayama K, Yamato O. Molecular epidemiology of canine GM1 gangliosidosis in the Shiba Inu breed in Japan: relationship between regional prevalence and carrier frequency. BMC Vet Res 2013; 9:132. [PMID: 23819787 PMCID: PMC3701567 DOI: 10.1186/1746-6148-9-132] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 07/02/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Canine GM1 gangliosidosis is a fatal disease in the Shiba Inu breed, which is one of the most popular traditional breeds in Japan and is maintained as a standard breed in many countries. Therefore, it is important to control and reduce the prevalence of GM1 gangliosidosis for maintaining the quality of this breed and to ensure supply of healthy dogs to prospective breeders and owners. This molecular epidemiological survey was performed to formulate an effective strategy for the control and prevention of this disease. RESULTS The survey was carried out among 590 clinically unaffected Shiba Inu dogs from the 8 districts of Japan, and a genotyping test was used to determine nation-wide and regional carrier frequencies. The number and native district of affected dogs identified in 16 years from 1997 to June 2013 were also surveyed retrospectively. Of the 590 dogs examined, 6 dogs (1.02%, 6/590) were carriers: 3 dogs (2.27%, 3/132) from the Kinki district and the other 3 dogs from the Hokkaido, Kanto, and Shikoku districts. The retrospective survey revealed 23 affected dogs, among which, 19 dogs (82.6%) were born within the last 7 years. Of the 23 affected dogs, 12 dogs (52.2%) were from the Kinki district. Pedigree analysis demonstrated that all the affected dogs and carriers with the pedigree information have a close blood relationship. CONCLUSIONS Our results showed that the current carrier frequency for GM1 gangliosidosis is on the average 1.02% in Japan and rather high in the Kinki district, which may be related to the high prevalence observed over the past 16 years in this region. This observation suggests that carrier dogs are distributed all over Japan; however, kennels in the Kinki district may face an increased risk of GM1 gangliosidosis. Therefore, for effective control and prevention of this disease, it is necessary to examine as many breeding dogs as possible from all regions of Japan, especially from kennels located in areas with high prevalence and carrier frequency.
Collapse
Affiliation(s)
- Mohammad M Uddin
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Kohrimoto, Kagoshima 890-0065, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Rigat BA, Tropak MB, Buttner J, Crushell E, Benedict D, Callahan JW, Martin DR, Mahuran DJ. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Mol Genet Metab 2012; 107:203-12. [PMID: 22784478 PMCID: PMC4010500 DOI: 10.1016/j.ymgme.2012.06.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Revised: 06/12/2012] [Accepted: 06/12/2012] [Indexed: 12/26/2022]
Abstract
Deficiencies of lysosomal β-D-galactosidase can result in GM1 gangliosidosis, a severe neurodegenerative disease characterized by massive neuronal storage of GM1 ganglioside in the brain. Currently there are no available therapies that can even slow the progression of this disease. Enzyme enhancement therapy utilizes small molecules that can often cross the blood brain barrier, but are also often competitive inhibitors of their target enzyme. It is a promising new approach for treating diseases, often caused by missense mutations, associated with dramatically reduced levels of functionally folded enzyme. Despite a number of positive reports based on assays performed with patient cells, skepticism persists that an inhibitor-based treatment can increase mutant enzyme activity in vivo. To date no appropriate animal model, i.e., one that recapitulates a responsive human genotype and clinical phenotype, has been reported that could be used to validate enzyme enhancement therapy. In this report, we identify a novel enzyme enhancement-agent, N-nonyl-deoxygalactonojirimycin, that enhances the mutant β-galactosidase activity in the lysosomes of a number of patient cell lines containing a variety of missense mutations. We then demonstrate that treatment of cells from a previously described, naturally occurring feline model (that biochemically, clinically and molecularly closely mimics GM1 gangliosidosis in humans) with this molecule, results in a robust enhancement of their mutant lysosomal β-galactosidase activity. These data indicate that the feline model could be used to validate this therapeutic approach and determine the relationship between the disease stage at which this therapy is initiated and the maximum clinical benefits obtainable.
Collapse
Affiliation(s)
- Brigitte A. Rigat
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
| | - Michael B. Tropak
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
| | - Justin Buttner
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
| | - Ellen Crushell
- Clinical & Metabolic Genetics, The Hospital for Sick Children, Toronto, Canada M5G 1X8
| | - Daphne Benedict
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
| | - John W. Callahan
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
- Department of Biochemistry, University of Toronto, Toronto, Canada M5S 1A8
| | - Douglas R. Martin
- Scott-Ritchey Research Center and Dept. Anatomy, Physiology & Pharmacology, College of Veterinary Medicine, Auburn University, AL 36849, USA
| | - Don J. Mahuran
- Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8
- Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Canada M5S 1A8
- Corresponding author at: Genetics & Genome Biology Department, The Hospital for Sick Children, Room 9146 A, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. Fax: +1 416 813 8700. (D.J. Mahuran)
| |
Collapse
|
11
|
Hasegawa D, Yamato O, Nakamoto Y, Ozawa T, Yabuki A, Itamoto K, Kuwabara T, Fujita M, Takahashi K, Mizoguchi S, Orima H. Serial MRI features of canine GM1 gangliosidosis: a possible imaging biomarker for diagnosis and progression of the disease. ScientificWorldJournal 2012; 2012:250197. [PMID: 22536126 PMCID: PMC3334264 DOI: 10.1100/2012/250197] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Accepted: 11/20/2011] [Indexed: 11/17/2022] Open
Abstract
GM1 gangliosidosis is a fatal neurodegenerative lysosomal storage disease caused by an autosomal recessively inherited deficiency of β-galactosidase activity. Effective therapies need to be developed to treat the disease. In Shiba Inu dogs, one of the canine GM1 gangliosidosis models, neurological signs of the disease, including ataxia, start at approximately 5 months of age and progress until the terminal stage at 12 to 15 months of age. In the present study, serial MR images were taken of an affected dog from a model colony of GM1 gangliosidosis and 4 sporadic clinical cases demonstrating the same mutation in order to characterize the MRI features of this canine GM1 gangliosidosis. By 2 months of age at the latest and persisting until the terminal stage of the disease, the MR findings consistently displayed diffuse hyperintensity in the white matter of the entire cerebrum on T2-weighted images. In addition, brain atrophy manifested at 9 months of age and progressed thereafter. Although a definitive diagnosis depends on biochemical and genetic analyses, these MR characteristics could serve as a diagnostic marker in suspect animals with or without neurological signs. Furthermore, serial changes in MR images could be used as a biomarker to noninvasively monitor the efficacy of newly developed therapeutic strategies.
Collapse
Affiliation(s)
- Daisuke Hasegawa
- Division of Veterinary Radiology, Department of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo 180-8602, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Rahman MM, Kawaguchi H, Miyoshi N, Yabuki A, Nakamoto Y, Ozawa T, Yamato O. Pathological features of salivary gland cysts in a Shiba dog with GM1 gangliosidosis: a possible misdiagnosis as malignancy. J Vet Med Sci 2011; 74:485-9. [PMID: 22083095 DOI: 10.1292/jvms.11-0309] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Salivary gland cysts are often concurrent with GM1 gangliosidosis in Shiba dogs. Although the etiology is unknown, these cysts may be misdiagnosed as malignant due to the accumulation of foamy cells. The present study investigated the cytological, histopathological, immunohistochemical and electron microscopic characteristics of salivary gland cysts in a Shiba dog affected with GM1 gangliosidosis. The salivary gland masses were surgically enucleated and examined clinicopathologically and pathologically in a 7-month-old Shiba dog with GM1 gangliosidosis. Many large cells with rich cytoplasm including vacuoles of various sizes, i.e., foamy cells, were observed in stamp smears from the cut-surface of the masses and histopathologically in major parts of the cyst wall. Some of these foamy cells presented features similar to a spider-web appearance. The foamy cells were confirmed to have originated from macrophages based on marked immunohistochemical expression of vimentin, HLA-DR, lysozyme and Iba1. An ultrastructural study demonstrated electron-dense vesicular structures in the vacuolated cells. Therefore, the masses were diagnosed pathologically as benign salivary gland cysts with accumulation of foamy cells. In conclusion, the histopathological features of the salivary gland cysts in this Shiba dog were similar to those of lipoma and/or liposarcoma. In such cases, immunohistochemical and ultrastructural examinations were useful in the differential diagnosis. Practitioners, clinical pathologists and pathologists should take GM1 gangliosidosis into consideration when they encounter salivary gland cysts in Shiba dogs.
Collapse
Affiliation(s)
- Mohammad Mahbubur Rahman
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan
| | | | | | | | | | | | | |
Collapse
|
13
|
Satoh H, Yamauchi T, Yamasaki M, Maede Y, Yabuki A, Chang HS, Asanuma T, Yamato O. Rapid detection of GM1 ganglioside in cerebrospinal fluid in dogs with GM1 gangliosidosis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Vet Diagn Invest 2011; 23:1202-7. [DOI: 10.1177/1040638711425592] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The concentration of GM1 (monosialotetrahexosyl ganglioside) in cerebrospinal fluid (CSF) is markedly increased in dogs with GM1 gangliosidosis due to GM1 accumulation in the central nervous system and leakage to the CSF. The present study established a rapid and simple method for detection of accumulated GM1 in the CSF in dogs with GM1 gangliosidosis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI TOF MS) and discusses the usefulness of this method for the rapid diagnosis and/or high-risk screening of this disease in domestic animals. Cerebrospinal fluid was collected from normal dogs and 4- to 11-month-old Shiba dogs with GM1 gangliosidosis. The MALDI TOF MS analysis was carried out in combination with a special sample plate and a simple desalting step on the plate. Specific signs of GM1 could be detected in the standard GM1 solutions at concentrations of 50 nmol/l or more. The signs were also clearly detected in CSF (131–618 nmol/l) in affected dogs, but not in normal canine CSF (12 ± 5 nmol/l, mean ± standard deviation). The results demonstrated that MALDI TOF MS can detect GM1 accumulated in canine CSF even in the early stage of the disease. In conclusion, the rapid detection of increased CSF GM1 using MALDI TOF MS is a useful method for diagnosis and/or screening for canine GM1 gangliosidosis.
Collapse
Affiliation(s)
- Hiroyuki Satoh
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Toyofumi Yamauchi
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Masahiro Yamasaki
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Yoshimitsu Maede
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Akira Yabuki
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Hye-Sook Chang
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Taketoshi Asanuma
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| | - Osamu Yamato
- Department of Veterinary Radiology, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan (Satoh, Asanuma)
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamauchi, Yamasaki, Maede)
- Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, Kagoshima, Japan (Yabuki, Chang, Yamato)
| |
Collapse
|
14
|
Kreutzer R, Kreutzer M, Sewell AC, Techangamsuwan S, Leeb T, Baumgärtner W. Impact of beta-galactosidase mutations on the expression of the canine lysosomal multienzyme complex. Biochim Biophys Acta Mol Basis Dis 2009; 1792:982-7. [PMID: 19607915 DOI: 10.1016/j.bbadis.2009.07.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2009] [Revised: 07/02/2009] [Accepted: 07/06/2009] [Indexed: 01/09/2023]
Abstract
beta-galactosidase (GLB1) forms a functional lysosomal multienzyme complex with lysosomal protective protein (PPCA) and neuraminidase 1 (NEU1) which is important for its intracellular processing and activity. Mutations in the beta-galactosidase gene cause the lysosomal storage disease G(M1)-gangliosidosis. In order to identify additional molecular changes associated with the presence of beta-galactosidase mutations, the expression of canine lysosomal multienzyme complex components in GLB1(+/+), GLB1(+/-) and GLB1(-/-) fibroblasts was investigated by quantitative RT-PCR, Western blot and enzymatic assays. Quantitative RT-PCR revealed differential regulation of total beta-galactosidase, beta-galactosidase variants and protective protein for beta-galactosidase gene (PPGB) in GLB1(+/-) and GLB1(-/-) compared to GLB1(+/+) fibroblasts. Furthermore, it was shown that PPGB levels gradually increased with the number of mutant beta-galactosidase alleles while no change in the NEU1 expression was observed. This is the first study that simultaneously examine the effect of GLB1(+/+), GLB1(+/-) and GLB1(-/-) genotypes on the expression of lysosomal multienzyme complex components. The findings reveal a possible adaptive process in GLB1 homozygous mutant and heterozygous individuals that could facilitate the design of efficient therapeutic strategies.
Collapse
Affiliation(s)
- Robert Kreutzer
- Department of Pathology, University of Veterinary Medicine, Hannover, Bünteweg 17, D-30559, Hannover, Germany.
| | | | | | | | | | | |
Collapse
|
15
|
NAKAMOTO Y, YAMATO O, ITAMOTO K, HASEGAWA D, OZAWA T, KATAKABE K, TSUKANE M, NAKAICHI M. Cranial MRI Findings for Three Shiba Dogs Diagnosed with GM 1-Gangliosidosis Using a Genetic Test. ACTA ACUST UNITED AC 2009. [DOI: 10.12935/jvma.62.219] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
Nagayasu A, Nakamura T, Yamato O, Tsuzuki K, Hosaka Y, Ueda H, Tangkawattana P, Takehana K. Morphological analysis of corneal opacity in Shiba dog with GM1 gangliosidosis. J Vet Med Sci 2008; 70:881-6. [PMID: 18840960 DOI: 10.1292/jvms.70.881] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
GM1 gangliosidosis is one of the inherited metabolic lysosomal storage disorders characterized by neurological symptoms caused by beta-galactosidase deficiency and consequent accumulation of GM1 ganglioside in neuronal cells. Shiba dogs affected with GM1 gangliosidosis have been found to suffer from corneal opacity. In our morphological analysis, keratocyte enlargement was induced by abnormal intracellular accumulation of neutral carbohydrates, resulting in the loss of normal arrangement of collagen fibrils in the opaque cornea was found to be associated with the disorder. We therefore conclude that corneal opacity in this Shiba dog with GM1 gangliosidosis may be caused by neutral carbohydrate accumulation in lysosomes, swelling and dysfunction of keratocytes, and subsequent irregular arrangement of collagen fibrils in the corneal proper substance.
Collapse
Affiliation(s)
- Aya Nagayasu
- Department of Veterinary Anatomy, Rakuno Gakuen University, Hokkaido, Japan
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Yamato O, Jo EO, Chang HS, Satoh H, Shoda T, Sato R, Uechi M, Kawasaki N, Naito Y, Yamasaki M, Maede Y, Arai T. Molecular Screening of Canine GM1 Gangliosidosis Using Blood Smear Specimens after Prolonged Storage: Detection of Carriers among Shiba Dogs in Northern Japan. J Vet Diagn Invest 2008; 20:68-71. [DOI: 10.1177/104063870802000113] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Molecular screening of GM1 gangliosidosis in Shiba dogs was carried out in northern Japan using blood smear specimens after prolonged storage. Of 125 specimens obtained from 3 veterinary teaching hospitals for this screening, 68 specimens (54%) were adequate for direct amplification in a polymerase chain reaction (PCR)-based DNA test, and the percentage of adequacy was different at each hospital (34%, 73%. and 100%), suggesting that the amount of blood on the smear and the storage condition of specimens may affect adequacy. Of the 68 dogs examined, 2 dogs (2.9%) were heterozygous carriers for this disease and the other dogs were all genotypically normal. The results suggest blood smear specimens can be useful for PCR testing after prolonged storage provided specimens contain a generous amount of blood and have been adequately stored. The study also suggests that GM1 gangliosidosis may be widely prevalent in the Shiba dog population in northern Japan.
Collapse
Affiliation(s)
- Osamu Yamato
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Eun-Og Jo
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Hye-Sook Chang
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Hiroyuki Satoh
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Toru Shoda
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Reeko Sato
- Department of Clinical Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka, Japan (Sato, Naito)
| | - Masami Uechi
- Veterinary Teaching Hospital, School of Veterinary Medicine & Animal Science. Kitasato University, Towada, Aomori, Japan (Uechi, Kawasaki)
| | - Naomi Kawasaki
- Veterinary Teaching Hospital, School of Veterinary Medicine & Animal Science. Kitasato University, Towada, Aomori, Japan (Uechi, Kawasaki)
| | - Yoshihisa Naito
- Department of Clinical Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka, Japan (Sato, Naito)
| | - Masahiro Yamasaki
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | - Yoshimitsu Maede
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (Yamato, Jo. Chang, Satoh, Shoda, Yamasaki, Maede)
| | | |
Collapse
|
18
|
Kreutzer R, Kreutzer M, Pröpsting MJ, Sewell AC, Leeb T, Naim HY, Baumgärtner W. Insights into post-translational processing of beta-galactosidase in an animal model resembling late infantile human G-gangliosidosis. J Cell Mol Med 2007; 12:1661-71. [PMID: 18088383 PMCID: PMC3918082 DOI: 10.1111/j.1582-4934.2007.00204.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
GM1-gangliosidosis is a lysosomal storage disorder caused by a deficiency of ß-galactosidase activity. Human GM1-gangliosidosis has been classified into three forms according to the age of clinical onset and specific biochemical parameters. In the present study, a canine model for type II late infantile human GM1-gangliosidosis was investigated ‘in vitro’ in detail. For a better understanding of the molecular pathogenesis underlying GM1-gangliosidosis the study focused on the analysis of the molecular events and subsequent intracellular protein trafficking of β-galactosidase. In the canine model the genetic defect results in exclusion or inclusion of exon 15 in the mRNA transcripts and to translation of two mutant precursor proteins. Intracellular localization, processing and enzymatic activity of these mutant proteins were investigated. The obtained results suggested that the β-galactosidase C-terminus encoded by exons 15 and 16 is necessary for correct C-terminal proteolytic processing and enzyme activity but does not affect the correct routing to the lysosomes. Both mutant protein precursors are enzymatically inactive, but are transported to the lysosomes clearly indicating that the amino acid sequences encoded by exons 15 and 16 are necessary for correct folding and association with protective protein/cathepsin A, whereas the routing to the lysosomes is not influenced. Thus, the investigated canine model is an appropriate animal model for the human late infantile form and represents a versatile system to test gene therapeutic approaches for human and canine GM1-gangliosidosis.
Collapse
Affiliation(s)
- R Kreutzer
- Department of Pathology, University of Veterinary Medicine, Hannover, Germany.
| | | | | | | | | | | | | |
Collapse
|
19
|
Satoh H, Yamato O, Asano T, Yonemura M, Yamauchi T, Hasegawa D, Orima H, Arai T, Yamasaki M, Maede Y. Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: possible use for assessment of a therapeutic regimen. Brain Res 2006; 1133:200-8. [PMID: 17196562 DOI: 10.1016/j.brainres.2006.11.039] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2006] [Revised: 11/15/2006] [Accepted: 11/16/2006] [Indexed: 11/17/2022]
Abstract
The present study investigated cerebrospinal fluid (CSF) biomarkers for estimating degeneration of the central nervous system (CNS) in experimental dogs with GM1 gangliosidosis and preliminarily evaluated the efficacy of long-term glucocorticoid therapy for GM1 gangliosidosis using the biomarkers identified here. GM1 gangliosidosis, a lysosomal storage disease that affects the brain and multiple systemic organs, is due to an autosomal recessively inherited deficiency of acid beta-galactosidase activity. Pathogenesis of GM1 gangliosidosis may include neuronal apoptosis and abnormal axoplasmic transport and inflammatory response, which are perhaps consequent to massive neuronal storage of GM1 ganglioside. In the present study, we assessed some possible CSF biomarkers, such as GM1 ganglioside, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), neuron-specific enolase (NSE) and myelin basic protein (MBP). Periodic studies demonstrated that GM1 ganglioside concentration, activities of AST and LDH, and concentrations of NSE and MBP in CSF were significantly higher in dogs with GM1 gangliosidosis than those in control dogs, and their changes were well related with the months of age and clinical course. In conclusion, GM1 ganglioside, AST, LDH, NSE and MBP could be utilized as CSF biomarkers showing CNS degeneration in dogs with GM1 gangliosidosis to evaluate the efficacy of novel therapies proposed for this disease. In addition, we preliminarily treated an affected dog with long-term oral administration of prednisolone and evaluated the efficacy of this therapeutic trial using CSF biomarkers determined in the present study. However, this treatment did not change either the clinical course or the CSF biomarkers of the affected dog, suggesting that glucocorticoid therapy would not be effective for treating GM1 gangliosidosis.
Collapse
Affiliation(s)
- Hiroyuki Satoh
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita-18 Nishi-9, Kita-ku, Sapporo 060-0818, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Yamato O, Kobayashi A, Satoh H, Endoh D, Shoda T, Masuoka Y, Hatakeyama A, Jo EO, Asano T, Yonemura M, Yamasaki M, Maede Y. Comparison of polymerase chain reaction-restriction fragment length polymorphism assay and enzyme assay for diagnosis of G(M1)-gangliosidosis in Shiba dogs. J Vet Diagn Invest 2004; 16:299-304. [PMID: 15305740 DOI: 10.1177/104063870401600407] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In the present study, diagnostic methods for canine G(M1)-gangliosidosis were examined by comparing a DNA mutation assay with an enzyme assay. Sixty-two Shiba dogs of a pedigree with G(M1)-gangliosidosis were differentiated into 3 genotypes, i.e., normal, heterozygous, and homozygous affected dogs, using a DNA mutation assay, which consists of polymerase chain reaction amplification and the determination of restriction fragment length polymorphisms. The beta-galactosidase activity in leukocytes, umbilical cords, and plasma was measured using 4-methylumbelliferyl beta-D-galactoside and p-nitrophenyl beta-D-galactoside as artificial substrates and compared among the 3 genotypes. The results showed that it was possible to identify homozygous dogs with the enzyme assay using leukocytes and umbilical cords. When using leukocytes, heterozygous carriers could be differentiated from normal dogs in many cases. However, the use of the DNA mutation assay is essential for a complete determination of heterozygous carriers because of the overlap in the distribution of enzyme activity between these 2 groups. When umbilical cords were used, heterozygous carriers could not be differentiated from normal dogs because of no significant difference in enzyme activity between these 2 groups. The beta-galactosidase activity in plasma was not applicable to the diagnosis and genotyping of G(M1)-gangliosidosis in Shiba dogs.
Collapse
Affiliation(s)
- Osamu Yamato
- Laboratory of Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|